By selecting the Yes option, leaving Amgen.sa option you understand that you are leaving the corporate page of Amgen Saudi Arabia and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Saudi Arabia is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Saudi Arabia. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Amgen is one of the world's leading biotechnology companies, present in more than 100 countries and with a global team of 23,000 employees.
With a 40-year history, the company was created to unlock scientific knowledge about biology and drive significant advances in health. That founding principle identifies us as a company strongly grounded in science and focused on substantially improving the quality of life for patients with serious illnesses around the world.
Amgen was one of the pioneering companies in the use of living cells to manufacture biological medicines, opening the way to the field of biotechnology: we created and gave visibility to the scientific and productive procedures that turned biotechnology into a source of therapies for patients. Worldwide.
At Amgen we develop innovative medicines for significant unmet medical needs focused on several therapeutic areas: oncology, hematology, bone health, inflammation, cardiovascular disease, neurology, and nephrology.
We have a robust portfolio of innovative medicines, and important projects underway, to lead the next generation in bio-manufacturing. Our research focuses on the study of innovative molecules, new indications for various drugs and biosimilar treatments.
Amgen has been operating in the Saudi market since 2017. This was marked by the establishment of the Amgen Scientific Office in Riyadh. In 2020, (Amgen Saudi Arabia Limited) transformed into a fully-fledged company after obtaining a foreign investment license. Since its inception, Amgen has been committed to achieving sustainable development of the healthcare level to build a healthier and more prosperous society and to continue providing innovative human therapeutics to patients in the Kingdom of Saudi Arabia in line with Vision 2030.
For over 40 years, Amgen has developed biologic treatment options for patients